阿斯利康在英国股市盘中大涨5.03%,引起了市场广泛关注。消息显示,该公司公布了2024年全年财报,总营收同比增长21%至540.73亿美元,创下历史新高。
导致阿斯利康盘中大涨的主要原因,源于公司2024年业绩表现强劲。公司2024年各业务版块毛利和营收均有显著增长,体现出公司整体业务的卓越发展态势。
从具体情况来看,阿斯利康旗下包括Tagrisso、Imfinzi和Enhertu在内的肿瘤药物销售额同比大涨24%,达223.53亿美元。心血管及代谢疾病产品Farxiga收入同比增长31%至77.17亿美元。新冠中和抗体Beyfortus销售额更是大涨205%至21.47亿美元。
除了利润优异的业绩表现,阿斯利康还披露了未来一系列有利发展前景,包括7种新药即将公布临床数据,以及计划到2030年推出至少20种新型创新药物等。投资者对公司长期高速发展的信心持续增强,推动了当日阿斯利康股价大涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.